Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β

BMC Medical Genomics

Raimondo Pannone³  Marco Borra³  Elio Biffali³  Giovanni Vacca¹  Vincenzo Bresciamorra¹  Giuseppe Orefice¹  Anna Sasso¹  Paolo Mondola¹  Bruna De Felice² 

[1] Department of Clinical Medicine and Surgery, University Federico II of Naples, Corso Umberto I, Naples 80131, Italy;DISTABIF, Department of of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Naples II, Via Vivaldi 43, 81100 Caserta, Italy;Zoological Station Anton Dohrn, Villa Comunale, Piazza Vittoria, Napoli 80121, Italy

关键词: snorRNAs;    microRNA;    sncRNA;    IFN-β;    Multiple sclerosis;   

Others  :  797034
DOI  :  10.1186/1755-8794-7-26

 received in 2012-11-01, accepted in 2014-05-07,  发布年份 2014

【 摘 要 】

Background

Non-coding small RNA molecules play pivotal roles in cellular and developmental processes by regulating gene expression at the post-transcriptional level. In human diseases, the roles of the non-coding small RNAs in specific degradation or translational suppression of the targeted mRNAs suggest a potential therapeutic approach of post-transcriptional gene silencing that targets the underlying disease etiology. The involvement of non-coding small RNAs in the pathogenesis of neurodegenerative diseases such as Alzheimer’s , Parkinson’s disease and Multiple Sclerosis has been demonstrated. Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, characterized by chronic inflammation, demyelination and scarring as well as a broad spectrum of signs and symptoms. The current standard treatment for SM is interferon ß (IFNß) that is less than ideal due to side effects. In this study we administered the standard IFN-ß treatment to Relapsing-Remitting MS patients, all responder to the therapy; then examined their sncRNA expression profiles in order to identify the ncRNAs that were associated with MS patients’ response to IFNß.

Methods

40 IFNß treated Relapsing-Remitting MS patients were enrolled. We analyzed the composition of the entire small transcriptome by a small RNA cloning method, using peripheral blood from Relapsing-Remitting MS patients at baseline and 3 and 6 months after the start of IFNß therapy. Real-time qPCR from the same patients group and from 20 additional patients was performed to profile miRNAs expression.

Results

Beside the altered expression of several miRNAs, our analyses revealed the differential expression of small nucleolar RNAs and misc-RNAs.For the first time, we found that the expression level of miR-26a-5p changed related to INF-β response. MiR-26a-5p expression was significantly higher in IFN-β treated RRMS patients at 3 months treatment, keeping quite stable at 6 months treatments.

Conclusions

Our results might provide insights into the mechanisms of action of IFN-β treatment in MS and provide fundamentals for the development of new biomarkers and/or therapeutic tools.

【 授权许可】

   
2014 De Felice et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kasper LH, Shoemaker J: Multiple sclerosis immunology: the healthy immune system vs the ms immune system. Neurology 2010, 74:S2-S8.
• [2]Hoffjan S, Akkad DA: The genetics of multiple sclerosis: an update 2010. Mol Cell Probes 2010, 24:237-243.
• [3]Salta E, De Strooper B: Non-coding RNAs with essential roles inneurodegenerative disorders. Lancet Neurol 2012, 2:189-200.
• [4]Abe M, Bonini NM: MicroRNAs and neurodegeneration: role and impact. Trends Cell Biol 2013, 23:30-36.
• [5]De Felice B, Guida M, Guida M, Coppola C, De Mieri G, Cotrufo R: A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 2012, 508:35-40. Epub 2012 Aug 8
• [6]Malone CD, Hannon GJ: Small RNAs as guardians of the genome. Cell 2009, 136:656-668.
• [7]Junker A: Pathophysiology of translational regulation by micrornas in multiple sclerosis. FEBS Lett 2011, 585:3738-3746.
• [8]Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005, 58:840-846.
• [9]Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
• [10]Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C: Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003, 61:184-189.
• [11]Held U, Heigenhauser L, Shang C, Kappos L, Polman C, Sylvia Lawry Centre for MS Research: Predictors of relapse rate in MS clinical trials. Neurology 2005, 65:1769-1773.
• [12]Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grässer FA, van Dyk LF, Ho CK, Shuman S, Chien M, Russo JJ, Ju J, Randall G, Lindenbach BD, Rice CM, Simon V, Ho DD, Zavolan M, Tuschl T: Identification of microRNAs of the herpesvirus family. Nat Methods 2005, 2:269-276.
• [13]Mendes ND, Freitas AT, Sagot MF: Current tools for the identification of miRNA genes and their targets. Nucleic Acids Res 2009, 37:2419-2433.
• [14]Smirnova L, Gräfe A, Seiler A, Schumacher S, Nitsch R, Wulczyn FG: Regulation of miRNA expression during neural cell specification. Eur J Neurosci 2005, 21:1469-1477.
• [15]Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D: Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005, 128:1016-1025.
• [16]Stathakis DG, Hoover KB, You Z, Bryant PJ: Human postsynaptic density-95 (PSD95): location of the gene (DLG4) and possible function in nonneural as well as in neural tissues. Genomics 1997, 44:71-82.
• [17]Shiraishi-Yamaguchi Y, Furuichi T: The homer family proteins. Genome Biol 2007, 2:206.
• [18]Junker A, Hohlfeld R, Meinl E: The emerging role of MicroRNAs in multiple sclerosis. Nat Rev Neurol 2011, 7:56-59.
• [19]Tufekci KU, Oner MG, Genc S, Genc K: MicroRNAs and multiple sclerosis. Autoimmune Dis 2011, 2011:807426.
• [20]Cox MB, Cairns MJ, Gandhi KS, Carroll AP, Moscovis S, Stewart GJ, Broadley S, Scott RJ, Booth DR, Lechner-Scott J, ANZgene Multiple Sclerosis Genetics Consortium: MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One 2010, 5:e12132. doi:10.1371/journal.pone.0012132
• [21]Kishore S, Stamm S: The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006, 311:230-232.
• [22]Royo H1, Bortolin ML, Seitz H, Cavaillé J: Small non-coding RNAs and genomic imprinting. Cytogenet Genome Res 2006, 113:99-108.
• [23]Brameier M, Herwig A, Reinhardt R, Walter L, Gruber J: Human box C/D snoRNAs with miRNA like functions expanding the range of regulatory RNAs. Nucleic Acids Res 2011, 39:675-686.
• [24]Bortolin-Cavaillé ML, Cavaillé J: The SNORD115 (H/MBII-52) and SNORD116 (H/MBII-85) gene clusters at the imprinted Prader-Willi locus generate canonical box C/D snoRNAs. Nucleic Acids Res 2012, 40:1-8.
• [25]Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, Wood WG, Higgs DR: Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 2003, 34:157-165.
• [26]Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T: Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One 2011, 6:e24604.
• [27]Frigo M, Cogo MG, Fusco ML, Gardinetti M, Frigeni B: Glutamate and multiple sclerosis. Curr Med Chem 2012, 19:1295-1299.
• [28]Rahn KA, Slusher BS, Kaplin AI: Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr Med Chem 2012, 19:1335-1345.
• [29]Yushchenko M, Mäder M, Elitok E, Bitsch A, Dressel A, Tumani H, Bogumil T, Kitze B, Poser S, Weber F: Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. JNeurol 2003, 250:1224-1228.
• [30]Jin S, Kawanokuchi J, Mizuno T, Wang J, Sonobe Y, Takeuchi H, Suzumura A: Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res 2007, 7(1179):140-146.
• [31]Vanheel A, Daniels R, Plaisance S, Baeten K, Hendriks JJ, Leprince P, Dumont D, Robben J, Brône B, Stinissen P, Noben JP, Hellings N: Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. PLoS One 2012, 7(4):e35544.
• [32]Czech MP: MicroRNAs as therapeutic targets. N Engl J Med 2006, 354:1194-1195.